Cipla Latest News

  1. Cipla has informed about statement of investor complaints for the quarter ended 31st December 2017.

    The above information is a part of company’s filings submitted to BSE.

    Date:19-01-2018
  2. Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, Cipla has informed about updates.

    The above in...

    Date:01-12-2017
  3. This step has been taken in order to align with company’s strategy to operate via a B2B model in Europe
    Date:01-12-2017
  4. This step has been taken in order to align with company’s strategy to operate via a B2B model in Europe
    Date:01-12-2017
  5. The company has received an approval for its product Q-TIB from World Health Organisation
    Date:30-11-2017
  6. It is looking to expand the business through more in-house launches and brand acquisitions in the coming quarters
    Date:30-11-2017
  7. Cipla has informed about schedule of Investor / Analyst Meetings of the company.

    The above information is a part of company’s filings submitted to BSE....

    Date:27-11-2017
  8. Cipla has informed about press release titled ‘Cipla Receives Final Approval for Generic Dacogen’.

    The above information is a part of company’s filings submitted to BSE....

    Date:20-11-2017
  9. Dacogen and its generic equivalents had US sales of approximately $180 million for the 12-month period ending September 2017
    Date:20-11-2017
  10. Cipla has informed about press release titled ‘Cipla Receives Final Approval for Generic Pulmicort Respules’.

    The above information is a part of company’s filings submitted to BSE.

    ...
    Date:17-11-2017
Return to Top
Connect with us Facebook
Connect with us Facebook
Connect with us Linkedin
Connect with us Pintrest
Connect with us Google Plus
Connect with us You Tube
Connect with us Mobile App
 
 
Request a Call Back
Mobile
Invalid Mobile Number
x
Thanks. We will call you shortly.